ArticlePsychiatry investigation2025
Association Between the (GT)26 Allele in the GRIN2A Promoter and Opioid Use Disorder.
Article in Psychiatry investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Crosstalk Between Glycinergic and N-Methyl-D-Aspartate Receptor-Mediated Glutamatergic Transmission in Behaviours Associated with Opioid Use Disorder.International journal of molecular sciences · 2025Review
- RNA-Seq Analysis of Morphine-Induced Gene Expression Changes in the Mouse Nucleus Accumbens.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveN-methyl-D-aspartate (NMDA) receptors are involved in the development of opioid use disorder. The (GT)n polymorphism (rs3219790) in the NMDA receptor 2A subunit gene (GRIN2A) has been proposed as a potential biomarker for risk of opioid use disorder. In this case-control study, we investigated the association between rs3219790 and opioid use disorder in a Chinese Han population.
methodsA total of 538 heroin dependent patients and 400 healthy controls were recruited. The genotypes of (GT)n repeats were determined using a polymerase chain reaction-amplifying fragment length polymorphism assay. The association of the (GT)n polymorphism with opioid use disorder and cravings was assessed.
resultsThe frequency of the (GT)26 allele in patients with opioid use disorder was significantly greater than that in the controls (p=0.029, odds ratio=1.264, 95% confidence interval=1.025-1.560), consistent with previous findings. Compared with homozygous carriers of short alleles, carriers of long alleles demonstrated significantly stronger drug cravings (p<0.05).
conclusionThe results confirm that the (GT)26 allele of rs3219790 in the GRIN2A promoter is associated with opioid use disorder. Additionally, a longer rs3219790 allele is correlated with stronger drug cravings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.